NCT02068586View on ClinicalTrials.gov

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

November 19, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Ciliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeIris MelanomaStage I Intraocular MelanomaStage IIA Intraocular MelanomaStage IIB Intraocular MelanomaStage IIIA Intraocular MelanomaStage IIIB Intraocular MelanomaStage IIIC Intraocular MelanomaStage I Uveal Melanoma AJCC V7Stage II Uveal Melanoma AJCC V7Stage III Uveal Melanoma AJCC V7
Interventions
DRUG

Sunitinib

Given PO

DRUG

Valproic Acid

Given PO

DRUG

Sunitinib Malate

Given PO

DRUG

Sunitinib Malate + Valproic Acid

Given PO

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER